Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients

This study has been completed.
Information provided by (Responsible Party):
Kyowa Hakko Kirin Company, Limited Identifier:
First received: August 14, 2006
Last updated: August 23, 2012
Last verified: August 2012
To assess the duration of severe neutropenia in cycle 1 of chemotherapy after treatment with a single injection of KRN125 or multiple daily injections of filgrastim.

Condition Intervention Phase
Drug: pegfilgrastim
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized Dose Finding Study of KRN125 (Pegfilgrastim) for the Treatment of Chemotherapy - Induced Neutropenia in Malignant Lymphoma

Resource links provided by NLM:

Further study details as provided by Kyowa Hakko Kirin Company, Limited:

Primary Outcome Measures:
  • To compare the duration of severe neutropenia

Enrollment: 107
Study Start Date: March 2006
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   20 Years to 74 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • patients diagnosed as malignant lymphoma
  • patients who were refractory to anthracycline or anthraquinone containing chemotherapy
  • patients who are going to receive ESHAP or CHASE treatment regimen
  • ECOG performance status =< 2
  • patients who have appropriate bone marrow, hepatic and renal functions
  • written informed consent

Exclusion Criteria:

  • double cancer
  • history of bone marrow transplantation or PBSCT
  • more than 2 prior chemotherapy regimens
  • primary hematologic disease such as myelodysplastic syndrome
  • previous radiotherapy within 4 weeks of enrollment
  • woman of childbearing potential who were either pregnant, breast feeding
  • patients who participated in other clinical trials within the last 4 weeks of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00364468

Tokai region
Aichi, Japan
Kyusyu region
Fukuoka, Nagasaki, Japan
Kanto region
Gunma, Saitama, Tokyo, Kanagawa, Japan
Hokkaido region
Hokkaido, Japan
Kinki region
Kyoto, Mie, Shiga, Japan
Tohoku region
Miyagi, Japan
Sponsors and Collaborators
Kyowa Hakko Kirin Company, Limited
Study Chair: Tomomitsu Hotta, MD Nagoya Medical Center
  More Information

Responsible Party: Kyowa Hakko Kirin Company, Limited Identifier: NCT00364468     History of Changes
Other Study ID Numbers: KRN125/05-A04 
Study First Received: August 14, 2006
Last Updated: August 23, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by Kyowa Hakko Kirin Company, Limited:
cancer patients

Additional relevant MeSH terms:
Hematologic Diseases
Leukocyte Disorders
Leukopenia processed this record on May 23, 2016